Biologics: Targets & Therapy (Feb 2021)
Convalescent Plasma for the Treatment of Severe COVID-19
Abstract
Massimo Franchini, Giancarlo Maria Liumbruno Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, ItalyCorrespondence: Massimo FranchiniDepartment of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, ItalyTel +039-0376-201234Fax +039-0376-220144Email [email protected]: The COVID-19 pandemic in 2020 is one of the worst catastrophic events in human history. Several non-specific antiviral drugs have been tried to defeat the SARS-CoV-2, with mixed results. Convalescent plasma from patients who have recovered from COVID-19 is one of the specific biologic therapies being considered to treat SARS-CoV-2 infection. Preliminary studies have shown that convalescent plasma, containing antibodies able to neutralize SARS-CoV-2, is promising in blocking viral replication and improving patients’ clinical symptoms. The results of several ongoing randomized controlled trials are, however, keenly awaited to definitively elucidate the safety and efficacy of this blood component in COVID-19. In this narrative review, we summarize the current evidence from the literature on the treatment of severe COVID-19 with convalescent plasma. A concise overview of the hypothesized mechanisms of action is also presented.Keywords: SARS-CoV-2, COVID-19, hyperimmune plasma, convalescent plasma, therapy
